← Back to Search

Radiopharmaceutical

131I-PSMA-1095 Radioligand Therapy (RLT) for Prostate Cancer (CROSSBOW Trial)

Phase 2
Waitlist Available
Led By Stephan Probst, MD
Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months post last dose of rlt
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment for men with advanced prostate cancer who have no other options. The treatment uses a radioactive substance that targets and kills cancer cells. Researchers will see how well this treatment works by measuring changes in a specific cancer marker in the blood.

Eligible Conditions
  • Prostate Cancer
  • Prostate Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months post last dose of rlt
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months post last dose of rlt for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Prostate-Specific Antigen
Secondary study objectives
Adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 131I-PSMA-1095 Radioligand Therapy (RLT)Experimental Treatment1 Intervention
Intravenous injection of 100 mCi of 131I-PSMA-1095 RLT, Q8 weeks up to a maximum of 4 doses

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
58 Previous Clinical Trials
21,205 Total Patients Enrolled
16 Trials studying Prostate Cancer
3,688 Patients Enrolled for Prostate Cancer
Stephan Probst, MDPrincipal InvestigatorJewish General Hospital
1 Previous Clinical Trials
2,000 Total Patients Enrolled
~2 spots leftby Nov 2025